Cargando…
Advances in the Lung Cancer Immunotherapy Approaches
Despite the progress in the comprehension of LC progression, risk, immunologic control, and treatment choices, it is still the primary cause of cancer-related death. LC cells possess a very low and heterogeneous antigenicity, which allows them to passively evade the anticancer defense of the immune...
Autores principales: | Padinharayil, Hafiza, Alappat, Reema Rose, Joy, Liji Maria, Anilkumar, Kavya V., Wilson, Cornelia M., George, Alex, Valsala Gopalakrishnan, Abilash, Madhyastha, Harishkumar, Ramesh, Thiyagarajan, Sathiyamoorthi, Ezhaveni, Lee, Jintae, Ganesan, Raja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693102/ https://www.ncbi.nlm.nih.gov/pubmed/36423060 http://dx.doi.org/10.3390/vaccines10111963 |
Ejemplares similares
-
Onco-Pathogen Mediated Cancer Progression and Associated Signaling Pathways in Cancer Development
por: Kannampuzha, Sandra, et al.
Publicado: (2023) -
Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer’s Impediments: Current Understanding and Therapeutic Implications
por: Katturajan, Ramkumar, et al.
Publicado: (2022) -
Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches
por: Murali, Reshma, et al.
Publicado: (2023) -
Recent Development and Application of “Nanozyme” Artificial Enzymes—A Review
por: Jeyachandran, Sivakamavalli, et al.
Publicado: (2023) -
The Cellular and Molecular Immunotherapy in Prostate Cancer
por: Mukherjee, Anirban Goutam, et al.
Publicado: (2022)